| 开盘价:-- | 最高价:-- | 最低价:-- | 52周最高价:-- | 52周最低价:-- |
| 成交量:-- | 平均成交量:-- | 市值:-- | 市盈率:-- | 预期市盈率:-- |
| 每股收益:-- | 贝塔系数:-- | 股息:-- | 收益率:-- | 总股本:-- |
| 证券代码:cris | 公司名称:居里 | 公司中文简称: |
| 公司简介： Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170, and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints. The company was founded on February 14, 2000 and is headquartered in Lexington, MA. |
||
| 公司网站： http://www.curis.com |
||
| 公司地址： 128 Spring Street Building C Suite 500 Lexington |
||